Search International and National Patent Collections

1. (WO2018108106) ANTI-CD19 HUMANIZED ANTIBODY AND IMMUNE EFFECTOR CELL TARGETING CD19

Pub. No.:    WO/2018/108106    International Application No.:    PCT/CN2017/115973
Publication Date: Fri Jun 22 01:59:59 CEST 2018 International Filing Date: Thu Dec 14 00:59:59 CET 2017
IPC: C07K 16/28
C12N 15/13
C12N 15/63
C12N 7/01
C12N 5/10
C07K 19/00
A61K 39/395
A61K 35/17
A61P 35/00
Applicants: CARSGEN THERAPEUTICS, LTD
科济生物医药(上海)有限公司
SHANGHAI CANCER INSTITUTE
上海市肿瘤研究所
Inventors: WANG, Peng
王鹏
GAO, Huiping
高慧萍
SHI, Zhimin
石志敏
LI, Zonghai
李宗海
Title: ANTI-CD19 HUMANIZED ANTIBODY AND IMMUNE EFFECTOR CELL TARGETING CD19
Abstract:
Disclosed are an anti-CD19 humanized antibody prepared from a murine monoclonal antibody, a chimeric antigen receptor containing the humanized antibody, and an immune cell expressing the humanized antibody. Not only does the humanized antibody of the present invention not produce an anti-antibody response (AAR) and a human anti-mouse antibody response (HAMA), but same also has better affinity than a murine antibody, and has excellent activity and safety, thereby providing a new means for treating CD19-expressing tumors.